Vortioxetine for Menopausal Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 12, 2015

Primary Completion Date

September 29, 2016

Study Completion Date

September 29, 2016

Conditions
DepressionMenopauseVasomotor DisturbanceHot FlashesSleep
Interventions
DRUG

vortioxetine

Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Takeda Pharmaceuticals North America, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT02234362 - Vortioxetine for Menopausal Depression | Biotech Hunter | Biotech Hunter